Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 5 versus AMPHETAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 5 versus AMPHETAMINE SULFATE.
ADDERALL 5 vs AMPHETAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Increases presynaptic release of dopamine and norepinephrine, blocks reuptake, and inhibits monoamine oxidase, resulting in CNS stimulation.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
5–60 mg/day orally in 1–3 divided doses, initial 5 mg once or twice daily, increase by 5 mg weekly.
None Documented
None Documented
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary pH >7.
Terminal elimination half-life: 10-13 hours in adults with acidic urine; prolonged to 16-34 hours with alkaline urine. In children, half-life is typically shorter (6-8 hours).
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
Renal excretion of unchanged amphetamine (approximately 30-40%) and its metabolites; urinary pH-dependent: acidic urine enhances elimination (up to 70% unchanged), alkaline urine reduces it. Minor biliary/fecal elimination (<10%).
Category C
Category D/X
CNS Stimulant
CNS Stimulant